Version 1
: Received: 29 September 2024 / Approved: 30 September 2024 / Online: 30 September 2024 (10:38:09 CEST)
How to cite:
Mahlab-Guri, K.; Komarova, I.; Kadar, L.; Nemet, S.; Cohen, R.; Radian-Sade, S.; Tova, A.; Guri, A.; Bezalel-Rosenberg, S.; Elbirt, D. COVID-19 Vaccinations, Infections and Outcomes among 784 People Living with HIV. Preprints2024, 2024092397. https://doi.org/10.20944/preprints202409.2397.v1
Mahlab-Guri, K.; Komarova, I.; Kadar, L.; Nemet, S.; Cohen, R.; Radian-Sade, S.; Tova, A.; Guri, A.; Bezalel-Rosenberg, S.; Elbirt, D. COVID-19 Vaccinations, Infections and Outcomes among 784 People Living with HIV. Preprints 2024, 2024092397. https://doi.org/10.20944/preprints202409.2397.v1
Mahlab-Guri, K.; Komarova, I.; Kadar, L.; Nemet, S.; Cohen, R.; Radian-Sade, S.; Tova, A.; Guri, A.; Bezalel-Rosenberg, S.; Elbirt, D. COVID-19 Vaccinations, Infections and Outcomes among 784 People Living with HIV. Preprints2024, 2024092397. https://doi.org/10.20944/preprints202409.2397.v1
APA Style
Mahlab-Guri, K., Komarova, I., Kadar, L., Nemet, S., Cohen, R., Radian-Sade, S., Tova, A., Guri, A., Bezalel-Rosenberg, S., & Elbirt, D. (2024). COVID-19 Vaccinations, Infections and Outcomes among 784 People Living with HIV. Preprints. https://doi.org/10.20944/preprints202409.2397.v1
Chicago/Turabian Style
Mahlab-Guri, K., Shira Bezalel-Rosenberg and Daniel Elbirt. 2024 "COVID-19 Vaccinations, Infections and Outcomes among 784 People Living with HIV" Preprints. https://doi.org/10.20944/preprints202409.2397.v1
Abstract
Introduction: Variants of COVID-19 are responsible for 700 million infections and 7 million deaths worldwide. Vaccinations have high efficiency in preventing infection and secondary benefits of reducing COVID-19 hospital admissions, attenuating disease severity and duration of illness. Conflicting reports were published regarding COVID-19 among PLWH. Objective: The aim of this study was to evaluate COVID-19 morbidity, hospitalization and the magnitude of immunological response to sequential BNT 162b2 mRNA vaccines in PLWH regarding demographic and clinical factors. Results: Our retrospective study included 784 PLWH who had at least one anti- SARS-CoV-2 antibody test between March 2021 and October 2021. Half of our patients (392) had CD4 cells count above 500 cells/µl, 40.2% (315) had 200<CD4<500 cells/µL and only 9.8% (77) had CD4 <200 cells/µL at their last laboratory workup. The mean age was 50.2±12.2 years. About 90% of our patients were given at least two doses of the BNT 1626b2 Pfizer vaccines, about 60% received three doses of the vaccine. About a quarter of our patients (27.3%) had COVID-19 infection. Only 6 patients required hospital admission. All six patients recovered from COVID-19 infection. Titers of COVID-19 antibodies were lower for patients with CD4 cells count of less than 200 cells/ µL in the first, second and third serological tests with statistical significance. In a multinomial logistic regression the influence of other factors such as age, sex, previous COVID-19 infection on first COVID-19 antibodies titers was not significant. Conclusions: PLWH are responsive to COVID-19 vaccines. As was expected, patients with higher CD4 cells count have higher titers of COVID-19 antibodies and less severe illness. Age, sex and previous COVID-19 infection did not significantly affect antibodies titers according to our study. Larger prospective studies with control groups are needed to further characterize immunologic response to COVID-19 vaccination among PLWH.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
